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Should the continued use of phenobarbitone for childhood
epilepsy in resource-poor countries be considered a form of
discrimination?  Phenobarbitone was recommended by the
World Health Organization (WHO) as the first-line agent for
the control of seizures,
1
but this has been contested on the
grounds that it is biased against resource-poor countries.
2
It
was first used as an anticonvulsant in 1912, but now has little
role to play in First-World countries where the newer-
generation agents are readily accessible.
Phenobarbitone monotherapy has equivalent efficacy to the
newer anticonvulsants (phenytoin, sodium valproate and
carbamazepine) in children with partial-onset and generalised
tonic-clonic seizures.
3
Phenobarbitone is cheap, readily available, and easy to use
and store. However, it has definite cognitive and behavioural
side-effects in many children.  It can exacerbate seizures in
about 35% of children, and extreme caution should be taken
with children who have a pre-morbid state of behavioural
problems or attention deficit hyperactivity disorder (ADHD).
Cognitive and behavioural concerns
All anticonvulsants have absolute cognitive side-effects.
4
Generally the severity of cognitive side-effects is mild, allowing
continuation of therapy, especially where there is a favourable
risk-benefit ratio. However, when critical learning functions are
affected the impact may be substantial. Routine clinical follow-
up of children with epilepsy is reported to be insufficiently
sensitive to evaluate cognitive functioning.
5
Neuropsycholo-
gical intelligence screens are required.
The majority of studies6-9 on phenobarbitone found
significant adverse effects on cognition. One study6 identified
an intelligence quotient drop of 8.4 points after 2 years on the
medication. Another study7 found that there was a reduction in
reading skills after 3 - 5 years on medication.  Significant
improvements in divided attention abilities were reported on
cessation of phenobarbitone.
9
Unfortunately, most studies assessing cognitive function in
relation to phenobarbitone have been deemed methodolo-
gically inadequate.4 A database of 1 357 articles assessing the
cognitive effects of anti-epileptic drugs published in peer-
reviewed journals between 1970 and 1998 identified only 1
phenobarbitone absolute side-effect study and 4 relative
comparison studies. However, the review concluded that
phenobarbitone had definite impact on higher functions.4
Studies have failed to appreciate dose-related effects. The
cognitive and side-effect profile of low-dose phenobarbitone (3
mg/kg/day) may differ from a 5 - 10 mg/kg/day dosage
regimen.  Little is known about how tolerance to the cognitive
effects of anti-epileptic drugs develops; failure to take this
factor into account may lead to false-positives in the evaluation





on phenobarbitone, especially in children, have
demonstrated irritability, hyperactivity, aggression,
inattentiveness, sleep disturbances and increased depression.
One study
11
reported that 76% of the children treated with
phenobarbitone experienced 1 or more behavioural side-effects
compared with 31% of children receiving other anti-epileptics.
Pal et al.
12
performed a controlled trial comparing the side-
effect profiles of phenobarbitone and phenytoin in rural Indian
children.  They found that the side-effect profile was similar in
both groups, with 17% of the children in the phenobarbitone
group experiencing behavioural complications and sleep
disturbances.  The study concluded that phenobarbitone was
an effective anticonvulsant with an acceptable side-effect
profile.
The co-morbidity of disorders associated with epilepsy is
well described.
13
Of children attending Red Cross Children’s
Hospital epilepsy clinic, 60% have associated learning and
behavioural disabilities. A proportion of children with epilepsy
have a predisposition to these disabilities as part of their
underlying neurological condition, and phenobarbitone can
‘expose’ them or exacerbate this tendency.
14
However, conflicting results are found when comparing data
from developed and resource-poor countries. Phenobarbitone’s
side-effect profile is reported to be less of an issue in resource-
poor countries, with figures in the region of 3.1 - 4%.
15,16
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Seizure aggravation and drug tolerance
At low dosage range phenobarbitone has an anti-absence
effect, while higher dosages may paradoxically result in
absence aggravation.
17
In addition, phenobarbitone exacerbates severe myoclonic
epilepsy of infancy (Dravet syndrome), infantile spasms,
Lennox-Gastaut syndrome and continuous spike and wave in
sleep (CSWS).
17
Although in isolation these syndromes are
relatively rare, when combined the potential impact is
significant. If one considers children with absence epilepsy and
children with these syndromes together, up to 35% will have
seizures potentially exacerbated.
18 
Most published studies have
been limited to the ‘safe’ epilepsies, viz. generalised tonic-
clonic seizures and partial seizures, while patients with
myoclonic epilepsy, drop attacks, and neurodegenerative
syndromes were excluded.
Cost and availability
Phenobarbitone is the most cost-effective of all anticonvulsants
currently in use. Alternatives such as phenytoin, carbama-
zepine and sodium valproate are 5, 15 and 20 times more
expensive. Cost of therapy is of the utmost importance as
poverty is considered the root cause of the large treatment gap
that currently exists in most resource-poor countries.19
The non-availability of anti-epileptic drugs is considered one
of the most important obstacles to the care of children with
epilepsy. Phenobarbitone is currently the only anticonvulsant
uniformly available throughout rural South Africa and most of
the rest of Africa. The simplicity of its use (i.e. long half-life,
once-daily administration, stability, and room temperature
storage) facilitates its use by poor uneducated households.
It is the only anticonvulsant ‘tried and tested’ in the rural
regions of resource-poor developing countries. Simple
community-based treatment protocols using phenobarbitone as
a first-line agent have been implemented successfully in
countries such as Malawi, Kenya, Mali and India.
12,15,20
A phenobarbitone treatment protocol is currently also being
implemented in 7 counties of 5 provinces in Northern and
Eastern China.
21
Phenobarbitone has also been selected for its simplicity;
primary health care workers can be trained to administer it.
The relevance of this becomes apparent when one considers
that some African countries have 1 doctor or less per 50 000
people.
Conclusion
Phenobarbitone is cheap, readily available, and easy to use and
store. It is effective against partial and generalised seizure
disorders. However, it has definite cognitive and behavioural
side-effects in many children. It can exacerbate seizures in
approximately 35% of children with epilepsy, and extreme
caution should be taken when using this drug in children with
a pre-morbid state of behavioural problems or ADHD. In other
words, used wisely and carefully at the lowest effective dosage
(3 mg/kg/day) this would be an excellent drug whose role in
the resource-poor countries has not expired.
Access to health care services is not just a basic need of
children, but also a fundamental human right. Ideally, the
choice of anti-epileptic drug for each child should be based on
seizure type and/or syndrome and the individual child’s
needs. The brutal reality is that in developing countries both
choice and supply of drugs are limited. Economic restraints
often require that a compromise be reached between individual
welfare and limited resources. Phenobarbitone currently has by
far the most favourable cost-efficacy ratio of all anticonvulsants
in use. As a result the WHO continues to advocate its use as
first-line anti-epileptic agent in developing countries. In both
China and India, the world’s two most populous nations,
phenobarbitone is used as the front-line anticonvulsant
through community-based health worker-driven projects, in an
attempt to reduce the treatment gap.
Typical absences would be the commonest form of epilepsy
in childhood potentially exacerbated by phenobarbitone use.
Health care workers can be trained to recognise simple
absences and thereby lessen the risk of aggravation with high-
dose phenobarbitone.
A study by Aldenkamp and Vermeulen
4
concluded that all
established anti-epileptic drugs have reported absolute
cognitive side-effects, but that the effects are definitely greater
for phenobarbitone.  Phenobarbitone was furthermore the only
anti-epileptic drug with absolute effects that concerned specific
higher-order cognitive memory function when compared with
no treatment.
The conflicting side-effect profiles found in reports from
developed versus resource-poor countries supports the notion
that research findings cannot be extrapolated from First-World
to Third-World children. One reason for the discrepancy in
side-effects reported in resource-poor countries could be that
parental demands and expectations are different, i.e.
expectations are higher in developed countries. Studies
examining  phenobarbitone dose-related effects in children in
resource-poor countries are lacking.
4
Disappointingly few
studies allow valid inferences to be drawn.
4
Unfortunately,
with the reduction of phenobarbitone use in developed
countries and the lack of readily available neuropsychological
testing in resource-poor countries, the likelihood of a definitive
study to assess the drug’s cognitive and behavioural impact is
low.
In the meantime the continued use of phenobarbitone in
childhood epilepsy should be advocated (as it is currently by
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Although we have achieved a great deal since being established in 1994, there is still a great deal to be done to
improve the sexual and reproductive health of the people of South Africa.
Young people (particularly young women) bear a disproportionate share of the burden of sexual ill-health.
Therefore, ideally, provision of sexual health information should begin at school. It should be made available in
ways that are appropriate in terms of gender, age and level of understanding, and be sensitive to local culture.
Our young people are our future and it is vital that they have access to good sexual and reproductive health
services so that they can make informed decisions about their health. Most particularly, they need to be able to
protect themselves from unplanned pregnancies, and from sexually transmitted infections such as HIV/AIDS.
With this in mind, we hope to expand our work with young people, and funding permitting, to establish a team
specifically to work with them to raise awareness about sexual and reproductive health issues and facilitate their
access to comprehensive, safe services.
We believe that the best way to prevent the spread of STI/HIV/AIDS is through awareness raising and behaviour
change initiatives. Our teams will continue to look for new ways to reach all communities with safer sex 
messages.
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the WHO) until the huge treatment gap between the rich and
poor nations is significantly lessened. Only once the gap
disappears would it be justified to shout ‘discrimination’. The
replacing anticonvulsant should ideally be as cost-effective as
phenobarbitone, but with a superior cognitive profile. Sodium
valproate currently qualifies as the most likely replacing agent,
with carbamazepine as an alternative.
Lastly, in a situation where phenobarbitone is the only
option it is important to maintain therapy at the lowest
effective level to minimise impact (3 mg/kg/day).
19
Childhood
is a precious time and a few years of cognitive disruption can
be severely detrimental to a child’s education and future.
Parents and carers must be fully informed of the potential side-
effects of all medications and have the right to demand the best
care for their children.
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